Longeveron’s Cell Therapy Shows Mixed Results in Aging FrailtyAging Frailty, Biotech, Cell Therapy, Clinical Trial Endpoints, Clinical Trials, Premarket Trading, R&D, WalkingLomecel-B – Longeveron’s proprietary off-the-shelf cell therapy for aging frailty – failed the six-minute walk test (6MWT) endpoint of a Phase IIb study, according to a statement published by the Miami-based biotech on Aug. 13. Read more August 14, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/08/Longeveron’s-Cell-Therapy-Shows-Mixed-Results-in-Aging-Frailty-BioSpace-8-13-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-08-14 13:53:382021-08-14 13:55:24Longeveron’s Cell Therapy Shows Mixed Results in Aging Frailty